Denali Therapeutics Inc.
No enriched coverage for $DNLI in the last 7 days.
Denali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.
Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue • Advanced TransportVehicle™ portfolio with two Alzheimer’s
Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. dnli-20260727 0001714899 FALSE 0001714899 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
Recent DNLI coverage spans financial news, earnings and mergers & acquisitions.
In the last 30 days, DNLI insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($398K). The most active reporter was Schuth Alexander O., COFO and Secretary, with 2 filings. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Commercial ramp and cash runway are the near-term drivers, while multiple neurodegeneration readouts are pushed into 1H 2027.
AVLAYAH launch traction and explicit Q3 revenue guidance are near-term fundamentals that can re-rate DNLI’s commercial execution and cash runway expectations.
The completed PRV asset sale is a balance-sheet cash inflow event that can reduce financing needs and potentially improve near-term liquidity optics.
Platform validation narrative can support valuation, but the article does not provide new DNLI-specific clinical outcomes.
The disclosed PRV sale is a concrete monetization event that can improve near-term cash visibility, but closing timing remains conditional.
alphai scores every news story that mentions DNLI with an AI model for sentiment and relevance, and aggregates insider trades from Denali Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Denali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.
6 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue • Advanced TransportVehicle™ portfolio with two Alzheimer’s
6 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. dnli-20260727 0001714899 FALSE 0001714899 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readBiogen reported at the Alzheimer’s Association International Conference that its experimental antisense drug diranersen, given via spinal injection, slowed cognitive decline in a subset of about 400 participants with mild cognitive impairment or mild Alzheimer’s. In one lowest-dose test, results showed a 26% reduction in decline versus placebo. Biogen plans a larger study; side effects included injection pain and temporary confusion.
6 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. dnli-20260612 0001714899 FALSE 0001714899 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
4 min readOppenheimer has reiterated its Buy rating for Denali Therapeutics (DNLI.US) and increased the target price to $40. This revision reflects the firm's continued confidence in Denali Therapeutics' stock.
2 min readDenali Therapeutics (DNLI) reported a narrower-than-expected loss in Q4 2025, with a loss of 73 cents per share against an estimated 75 cents. The company is focused on the potential commercial launch of tividenofusp alfa for Hunter syndrome, with the FDA extending its review timeline to April 5, 2026. Denali also provided updates on other pipeline candidates, including DNL126 for Sanfilippo syndrome type A, and collaborations with Takeda, Biogen, and Sanofi.
4 min readDenali Therapeutics has announced the pricing of a public offering of 9.14 million shares at $17.50 each. This development follows a recent plan for a $200 million public offering and other significant events like analyst target adjustments and royalty funding agreements. The company continues to advance its clinical development programs for neurodegenerative and lysosomal storage diseases.
3 min readDenali Therapeutics (NASDAQ: DNLI) has priced an underwritten public offering of 9,142,857 common shares at $17.50 per share, alongside pre-funded warrants for 2,285,714 shares at $17.49 each. This offering is expected to generate gross proceeds of approximately $200 million and is anticipated to close around December 11, 2025. The company has also granted underwriters a 30-day option to purchase up to an additional 1,714,285 shares.
2 min readDenali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
4 min read
